Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Trial Profile

Phase 2a, Double-blind, Randomized, Placebo-controlled, Crossover Study to Evaluate the Safety and Efficacy of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Mar 2017

At a glance

  • Drugs Dextromethorphan/quinidine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Avanir Pharmaceuticals
  • Most Recent Events

    • 30 Mar 2017 Primary endpoint (Dyskinesia severity assessed by Unified Dyskinesia Rating Scale (UDysRS), part 3 AUC over the 2-hour levodopa infusion period) has not been met, according to results published in the Movement Disorders Journal.
    • 30 Mar 2017 Results published in the Movement Disorders Journal.
    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top